Triplebar

Executive Summary

Triplebar is a biotechnology company that integrates artificial intelligence with high-throughput microfluidics to dramatically accelerate biological discovery and engineering. Founded in 2020 and based in Emeryville, California, the company's platform explores vast genetic search spaces to generate functional biological datasets and products. Triplebar aims to address global challenges in climate, food security, and healthcare by developing solutions in biologics production, enzyme engineering, and cell therapy. By leveraging AI-driven design and microfluidic screening, the company can rapidly iterate through millions of genetic variants, reducing the time and cost of developing novel biomolecules. This approach has broad applications, from designing more efficient industrial enzymes to creating next-generation therapeutic antibodies. Triplebar's technology positions it as a key enabler in the convergence of AI and synthetic biology, with the potential to unlock breakthroughs that were previously unattainable due to the sheer scale of biological exploration required.

Upcoming Catalysts (preview)

• Q2 2026Strategic partnership with a major pharmaceutical or industrial biotech company60% success
• Q3 2026Series B funding round exceeding $30 million70% success
• Q4 2026Publication or preprint demonstrating platform validation in peer-reviewed journal80% success